Carlos Rodriguez is Executive Director of Corporate Development at Aktis Oncology, where he is responsible for business development and corporate strategy to advance the company’s growing portfolio of radiopharmaceuticals. Prior to Aktis, Carlos was Director of Business Development at Evelo Biosciences, a publicly-traded clinical-stage biotechnology company founded by Flagship Pioneering. At Evelo, Carlos led various initiatives across product development, corporate strategy, and technical operations and supported several financings, including the company’s initial public offering and venture debt placement. Earlier in his career, Carlos advised biotechnology and pharmaceutical clients as an investment banker at Credit Suisse and a strategy consultant at IMS Consulting Group. He has been named an HBS Blavatnik Fellow, Credit Suisse Scholar, Flare Capital Scholar, and Rock Health Fellow. Carlos earned an AB in economics from Princeton University and an MBA from Harvard Business School. In his free time, Carlos enjoys mentoring early career professionals interested in entrepreneurship and innovation.